Pancreatic Cancer Research

ResearcherYamagata UniversityActive in the last 2 years

Fuyuhiko Motoi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7601-8395; OpenAlex author ID A5039507236. Sources: OpenAlex.

Their work

Papers
89 (first author 11, last author 5)
Trials
0
Grants
0
Labs led
0
Collaborators
172
Papers, trials and grants by year

2011: 5 papers · 2012: 1 paper · 2013: 7 papers · 2014: 2 papers · 2015: 5 papers · 2016: 5 papers · 2017: 9 papers · 2018: 3 papers · 2019: 8 papers · 2020: 12 papers · 2021: 11 papers · 2022: 4 papers · 2023: 6 papers · 2024: 1 paper · 2025: 5 papers · 2026: 5 papers

Papers 50 of 89

  1. Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2026.1810↗
  2. Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed Using a Time-Dependent Cox Regression M… Co-author DOI 10.1002/jhbp.70054↗
  3. Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II/III Prep-02/JSAP0… First author DOI 10.1097/sla.0000000000006730↗
  4. Predictive Factors for Occult Metastases in Clinically M0 Pancreatic Cancer: A Prospective Multicenter Analysis of Staging Laparoscopy. Co-author DOI 10.1245/s10434-026-20728-8↗
  5. [A Case of Pancreatic Cancer Treated with Carbon Ion Radiotherapy for Oligohepatic Metastatic Recurrence after Conversion Surgery]. Last author PMID 41555174↗
  6. Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter… Co-author DOI 10.1002/ags3.70001↗
  7. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  8. Local Recurrence and Survival Outcomes after Portal Vein/Superior Mesenteric Vein Separation without Resection Preceding Neoadjuvant Therapy for Pancreatic Duc… Co-author DOI 10.1097/mpa.0000000000002503↗
  9. Favorable Response Defined by CA19-9 Reduction After Neoadjuvant Treatment for Pancreatic Cancer. First author DOI 10.1245/s10434-025-18084-0↗
  10. ASO Author Reflections: How to Evaluate CA19-9 Response to Neoadjuvant Treatment for Resectable Pancreatic Cancer?: Reduced Value or Reduction Rate? Co-author DOI 10.1245/s10434-025-18169-w↗
  11. Familial Intraductal Papillary Mucinous Neoplasm Associated With the Germline MSH6 Missense Variant and Progression of Pancreatic cancer. Last author DOI 10.1097/mpa.0000000000002313↗
  12. Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical … Co-author DOI 10.1002/jhbp.1282↗
  13. TWIST1 is a prognostic factor for neoadjuvant chemotherapy for patients with resectable pancreatic cancer: a preliminary study. Co-author DOI 10.1007/s00595-023-02655-3↗
  14. Expression of Corticotropin-Releasing Hormone and Its Receptors May Be Associated With Survival Rate in Pancreatic Cancer. First author DOI 10.1016/j.gastha.2022.09.003↗
  15. Negative prognostic impact of sarcopenia before and after neoadjuvant chemotherapy for pancreatic cancer. Co-author DOI 10.1016/j.pan.2022.11.010↗
  16. CA19-9 With Two-stage Resection Is Useful for Conversion Surgery in PDAC With Synchronous Oligometastases. Co-author DOI 10.21873/anticanres.16724↗
  17. [Treatment Experience of Chemotherapy and Carbon-Ion Radiotherapy followed by Curative Conversion Surgery for Initially Locally Advanced Unresectable Pancreati… Last author PMID 38303264↗
  18. Levels of tumor markers CEA/CA 19-9 in serum and peritoneal lavage predict postoperative recurrence in patients with pancreatic cancer. Co-author DOI 10.1002/ags3.12597↗
  19. Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma w… Co-author DOI 10.1186/s13063-022-06049-7↗
  20. Impact of Tumor-Derived DNA Testing in Peritoneal Lavage of Pancreatic Cancer Patients with and Without Occult Intra-Abdominal Metastases. Co-author DOI 10.1245/s10434-021-10997-w↗
  21. Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study. Co-author DOI 10.21873/anticanres.15547↗
  22. Germline DNA damage repair gene mutations in pancreatic cancer patients with personal/family histories of pancreas/breast/ovarian/prostate cancer in a Japanese… Co-author DOI 10.1002/ags3.12482↗
  23. Precise anatomical resection based on structures of nerve and fibrous tissue around the superior mesenteric artery for mesopancreas dissection in pancreaticodu… Co-author DOI 10.1002/jhbp.879↗
  24. Circulating tumor DNA as a predictive marker for occult metastases in pancreatic cancer patients with radiographically non-metastatic disease. Co-author DOI 10.1002/jhbp.993↗
  25. Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases. Co-author DOI 10.1007/s00595-020-02121-4↗
  26. Prognostic value of an inflammation-based nutritional score for patients with initially unresectable pancreatic adenocarcinoma undergoing conversion surgery fo… Co-author DOI 10.1007/s00595-021-02279-5↗
  27. Silencing of LRRFIP1 enhances the sensitivity of gemcitabine in pancreatic cancer cells by activating JNK/c-Jun signaling. Co-author DOI 10.1016/j.pan.2021.02.018↗
  28. Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up… Co-author DOI 10.1245/s10434-021-09718-0↗
  29. ASO Author Reflections: Preceding Systemic Chemotherapy Might Provide Better Prognosis for Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology. Co-author DOI 10.1245/s10434-021-09755-9↗
  30. Overcoming acquired chemo-resistance to gemcitabine: implications from the perspective of multi-modal therapy including surgery for pancreatic cancer. Co-author DOI 10.20517/cdr.2021.75↗
  31. Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.21037/jgo-20-243↗
  32. Defining the Optimal Method for Measuring Metabolic Tumor Volume on Preoperative 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography as a P… Co-author DOI 10.3389/fonc.2021.646141↗
  33. Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol? Co-author DOI 10.1002/ags3.12311↗
  34. Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.1002/bjs.11792↗
  35. Prognostic indicators in pancreatic cancer patients undergoing total pancreatectomy. Co-author DOI 10.1007/s00595-019-01924-4↗
  36. Methylation-mediated silencing of the LIM homeobox 6 (LHX6) gene promotes cell proliferation in human pancreatic cancer. Co-author DOI 10.1016/j.bbrc.2020.03.120↗
  37. Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.08.022↗
  38. Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy. Co-author DOI 10.1016/j.surg.2019.12.008↗
  39. Prognostic value of FDG-PET radiomics with machine learning in pancreatic cancer. Co-author DOI 10.1038/s41598-020-73237-3↗
  40. Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma. Co-author DOI 10.1093/jjco/hyaa018↗
  41. Epigenetic inactivation of IRX4 is responsible for acceleration of cell growth in human pancreatic cancer. Co-author DOI 10.1111/cas.14644↗
  42. Stromal expression of hemopexin is associated with lymph-node metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0235904↗
  43. [A Case of Aortitis Caused by a Granulocyte-Colony-Stimulating Factor during Chemotherapy for Pancreatic Cancer]. Co-author PMID 32408335↗
  44. [A Case of Initially Locally Advanced Pancreatic Cancer Curatively Resected after Carbon-Ion Radiotherapy with Gemcitabine]. Co-author PMID 33468929↗
  45. Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively … Co-author DOI 10.1007/s00268-018-4814-4↗
  46. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. First author DOI 10.1007/s00535-018-1506-7↗
  47. Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comp… Last author DOI 10.1007/s00595-019-01786-w↗
  48. Collagen gel droplet-embedded culture drug sensitivity test (CD-DST) predicts the effect of adjuvant chemotherapy on pancreatic cancer. First author DOI 10.1007/s00595-019-01842-5↗
  49. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Co-author DOI 10.1093/jjco/hyy190↗
  50. Conversion surgery for positive peritoneal washing cytology in pancreatic cancer. Co-author DOI 10.1136/bcr-2019-229993↗

Closest collaborators

The 25 strongest of 172 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michiaki Unno · 77 shared papers, 2011–2026 · strength 7.36
  2. Masamichi Mizuma · 38 shared papers, 2013–2026 · strength 4.28
  3. Kei Nakagawa · 26 shared papers, 2013–2023 · strength 2.60
  4. Sohei Satoi · 24 shared papers, 2011–2026 · strength 2.21
  5. Takanori Morikawa · 22 shared papers, 2011–2023 · strength 2.11
  6. Tatsuo Hata · 16 shared papers, 2016–2023 · strength 1.82
  7. Kyohei Ariake · 16 shared papers, 2017–2026 · strength 1.67
  8. Shimpei Maeda · 16 shared papers, 2011–2026 · strength 1.56
  9. Shuichi Aoki · 12 shared papers, 2013–2026 · strength 1.50
  10. Tatsuyuki Takadate · 17 shared papers, 2011–2023 · strength 1.45
  11. Kenichiro Uemura · 15 shared papers, 2015–2026 · strength 1.30
  12. Masahiro Iseki · 10 shared papers, 2017–2026 · strength 1.28
  13. Ippei Matsumoto · 16 shared papers, 2014–2026 · strength 1.21
  14. So Yamaki · 7 shared papers, 2020–2026 · strength 1.08
  15. Masayuki Sho · 15 shared papers, 2014–2026 · strength 1.04
  16. Daisuke Hashimoto · 6 shared papers, 2021–2026 · strength 0.99
  17. Goro Honda · 16 shared papers, 2014–2022 · strength 0.97
  18. Kei Kawaguchi · 12 shared papers, 2012–2023 · strength 0.96
  19. Satoshi Hirano · 6 shared papers, 2020–2026 · strength 0.91
  20. Yuya Ashitomi · 3 shared papers, 2023–2025 · strength 0.90
  21. Hiroki Yamaue · 14 shared papers, 2014–2022 · strength 0.82
  22. Tsutomu Fujii · 6 shared papers, 2017–2026 · strength 0.79
  23. Atsushi Oba · 4 shared papers, 2025–2026 · strength 0.77
  24. Koetsu Inoue · 4 shared papers, 2023–2026 · strength 0.75
  25. Yoshiaki Murakami · 13 shared papers, 2014–2020 · strength 0.70

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.